Moving past the marker versus mediator debate

Circulation Research

Volumn 114, Issue 4, 2014, Pages 594-595

  Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6;

CARDIOVASCULAR FUNCTION; CLINICAL TRIAL (TOPIC); DRUG EFFECT; EDITORIALS; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; NOTE; THROMBOSIS;

ATHEROTHROMBOSIS; C-REACTIVE PROTEIN; CLINICAL TRIALS; EDITORIALS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6;

C-REACTIVE PROTEIN; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; HUMANS; INFLAMMATION; MALE;

EID: 84894497197     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.303215     Document Type: Editorial

References (18)

1. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A in severe unstable angina. N Engl J Med 1994;331:417-424
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979
3. Maseri A. Inflammation, atherosclerosis, and ischemic events-exploring the hidden side of the moon. N Engl J Med. 1997;336:1014-1016
4. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-Analysis. Lancet. 2010;375:132-140
5. Lane T, Wassef N, Pooole S, Mistry Y, Lachmann HJ, Gillmore JD, Hawkins PN, Pepys MB. Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res. 2014;114:672-676
6. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217-1221
7. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325
8. Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease [published online ahead of print November 7, 2013]. Eur Heart J. doi: 10.1093/eurheartj/eht398: Http://eurheartj.oxfordjournals. org/content/early/2013/11/07/eurheartj.eht398.extract. Accessed January 31, 2014
9. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361
10. Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-Analysis of 82 studies. Lancet. 2012;379:1205-1213
11. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: A Mendelian randomisation analysis. Lancet. 2012;379:1214-1224
12. Ridker PM, Rifai N, Pfeffer M, Sacks F, Braunwald E. Long-Term effects of Pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-235
13. Braunwald E. Creating controversy where none exists: The important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. Eur Heart J. 2012;33:430-432
14. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38
15. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28
16. Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013;128:2395-2403
17. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605
18. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199-207.e15